The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial

Omid Toupchian, Shima Abdollahi, Amin Salehi-Abargouei, Javad Heshmati, Cain C T Clark, Mohammad Hasan Sheikhha, Hossein Fallahzadeh, Hassan Mozaffari-Khosravi

    Research output: Contribution to journalArticlepeer-review

    3 Citations (Scopus)
    16 Downloads (Pure)

    Abstract

    The present study sought to evaluate the effect of resveratrol supplementation on mRNA expression levels of peroxisome proliferator-activated receptor alpha (PPARα), p53, p21, p16, and serum levels of cluster of differentiation 163 (CD163) to TNF-like weak inducer of apoptosis (TWEAK) ratio in patients with type 2 diabetes. In this double-blind randomized controlled trial, 71 patients were randomly assigned to receive either 1,000 mg of trans-resveratrol or placebo (methyl cellulose) for 8 weeks. Expression levels of genes of interest, and serum levels of sCD163 and sTWEAK were assessed at baseline and at the end of the study. Resveratrol supplementation significantly increased mRNA expression levels of p53 and p21 genes, compared with the placebo group (fold change of p53 = 1.29, p = .04; fold change of p21 = 1.46, p = .006). However, no significant effect on expression levels of PPARα and p16 genes was observed after supplementation. In addition, resveratrol significantly reduced serum levels of sCD163/sTWEAK ratio compared with the placebo group (p = .003). Resveratrol supplementation resulted in significant changes in p53 and p21 genes expression, while serum levels of sCD163/sTWEAK ratio also improved in the resveratrol group, without any significant change in adjusted sCD163 levels. More research is needed to confirm the beneficial effects of resveratrol for patients with diabetes.

    Original languageEnglish
    Pages (from-to)3205-3213
    Number of pages9
    JournalPhytotherapy Research
    Volume35
    Issue number6
    Early online date13 Feb 2021
    DOIs
    Publication statusPublished - Jun 2021

    Bibliographical note

    This is the peer reviewed version of the following article: Toupchian, O, Abdollahi, S, Salehi-Abargouei, A, Heshmati, J, Clark, CCT, Sheikhha, MH, Fallahzadeh, H & Mozaffari-Khosravi, H 2021, 'The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial', Phytotherapy Research, vol. 35, no. 6, pp. 3205-3213, which has been published in final form at https://dx.doi.org/10.1002/ptr.7031. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

    Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders.

    Funder

    Shahid Sadoughi University of Medical Sciences (grant no: 4694) and Iran's National Science Foundation (INSF) (grant no: 96010660),.

    Keywords

    • cardiovascular diseases
    • resveratrol
    • sCD163
    • sTWEAK
    • type 2 diabetes mellitus

    ASJC Scopus subject areas

    • Pharmacology

    Fingerprint

    Dive into the research topics of 'The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial'. Together they form a unique fingerprint.

    Cite this